Surgical resection of metastatic melanoma in the era of immunotherapy and targeted therapy.

IF 1 Q4 ONCOLOGY Melanoma Management Pub Date : 2017-03-01 Epub Date: 2017-02-21 DOI:10.2217/mmt-2016-0018

Richard Tyrell, Camila Antia, Sharon Stanley, Gary B Deutsch

引用次数: 18

Abstract

Melanoma is the deadliest form of skin cancer and one of the few malignancies whose incidence is on the rise. The treatment of metastatic melanoma continues to be quite challenging, although in recent years, there has been significant progress. Current National Comprehensive Cancer Network guidelines list immunotherapy, chemotherapy, surgery and clinical trials as potential options for patients with metastatic disease but do not clearly recommend which is superior. Additionally, when utilizing combined modality treatment there are no clear guidelines for the optimal timing of surgery in the treatment of metastatic melanoma. In this paper we sought to compile the current evidence and on-going trials in order to provide a comprehensive review of the different options available and underway in regards to the treatment of metastatic melanoma. It is clear that with the responses now seen with systemic immunotherapies and targeted therapies, an expanded role for surgery is the logical next step.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

免疫治疗和靶向治疗时代转移性黑色素瘤的手术切除。

黑色素瘤是皮肤癌中最致命的一种，也是发病率呈上升趋势的少数恶性肿瘤之一。转移性黑色素瘤的治疗仍然相当具有挑战性，尽管近年来已经取得了重大进展。目前的国家综合癌症网络指南将免疫治疗、化疗、手术和临床试验列为转移性疾病患者的潜在选择，但没有明确推荐哪一种更好。此外，当使用联合治疗方式时，对于转移性黑色素瘤治疗的最佳手术时间没有明确的指导方针。在这篇论文中，我们试图汇编当前的证据和正在进行的试验，以提供一个关于转移性黑色素瘤治疗的不同选择的全面回顾。很明显，随着现在在全身免疫治疗和靶向治疗中看到的反应，下一步手术的扩大作用是合乎逻辑的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Melanoma Management ONCOLOGY-

CiteScore

5.10

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Skin cancer is on the rise. According to the World Health Organization, 132,000 melanoma skin cancers occur globally each year. While early-stage melanoma is usually relatively easy to treat, once disease spreads prognosis worsens considerably. Therefore, research into combating advanced-stage melanoma is a high priority. New and emerging therapies, such as monoclonal antibodies, B-RAF and KIT inhibitors, antiangiogenic agents and novel chemotherapy approaches hold promise for prolonging survival, but the search for a cure is ongoing. Melanoma Management publishes high-quality peer-reviewed articles on all aspects of melanoma, from prevention to diagnosis and from treatment of early-stage disease to late-stage melanoma and metastasis. The journal presents the latest research findings in melanoma research and treatment, together with authoritative reviews, cutting-edge editorials and perspectives that highlight hot topics and controversy in the field. Independent drug evaluations assess newly approved medications and their role in clinical practice. Key topics covered include: Risk factors, prevention and sun safety education Diagnosis, staging and grading Surgical excision of melanoma lesions Sentinel lymph node biopsy Biological therapies, including immunotherapy and vaccination Novel chemotherapy options Treatment of metastasis Prevention of recurrence Patient care and quality of life.